Yanina Rubinshteyn, MD
Family Medicine · Rego Park, NYNPI 1285680728
Payments from drug & device makers
Across 302 payments — averaging $20.87 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$913
- AstraZeneca$745
- Amgen$648
- Amarin Pharma, Inc.$623
- GSK$480
- Aimmune Therapeutics, Inc.$367
- plus $3K from 29 others
What the payments were for
- Food & beverage$6,290100%
- Education$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $913 |
| AstraZeneca | 33 | $745 |
| Amgen(2 entities) | 39 | $648 |
| Amarin Pharma, Inc. | 31 | $623 |
| GSK | 19 | $480 |
| Aimmune Therapeutics, Inc. | 14 | $367 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 19 | $320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 11 | $187 |
| Pfizer | 9 | $175 |
| Lilly USA, LLC | 8 | $155 |
| Merck | 7 | $140 |
| Ironwood Pharmaceuticals, Inc | 7 | $139 |
| EMD Serono, Inc. | 1 | $125 |
| Scilex Pharmaceuticals Inc. | 6 | $123 |
| Nestle Healthcare Nutrition Inc. | 6 | $123 |
| Ardelyx, Inc. | 4 | $113 |
| Boehringer Ingelheim | 6 | $111 |
| Amneal Pharmaceuticals LLC | 5 | $101 |
| E.r. Squibb & Sons, L.L.C. | 4 | $91 |
| Novo Nordisk | 4 | $89 |
| Kowa Pharmaceuticals America, Inc. | 3 | $73 |
| Astellas Pharma US Inc | 3 | $64 |
| Johnson & Johnson | 3 | $59 |
| Exact Sciences | 2 | $55 |
| Azurity Pharmaceuticals, Inc. | 2 | $43 |
| Verona Pharma, Inc. | 2 | $38 |
| Bausch Health US, LLC | 2 | $36 |
| Coopersurgical, Inc. | 1 | $25 |
| Vivus LLC | 1 | $24 |
| Corcept Therapeutics | 1 | $23 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $22 |
| Renalytix AI, Inc. | 1 | $20 |
| Sunovion Pharmaceuticals Inc. | 1 | $20 |
| Cumberland Pharmaceuticals, Inc. | 1 | $17 |
| Xeris Pharmaceuticals, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,304 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Diclofenac Sodium | 658 | $421,408 |
| LinzessLinaclotide | 704 | $363,005 |
| ZenpepLipase/Protease/Amylase | 285 | $276,797 |
| CreonLipase/Protease/Amylase | 316 | $238,851 |
| JanumetSitagliptin Phos/Metformin Hcl | 228 | $136,182 |
| FarxigaDapagliflozin Propanediol | 239 | $130,758 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 67 | $130,542 |
| Dihydroergotamine Mesylate | 92 | $124,387 |
| VascepaIcosapent Ethyl | 492 | $111,967 |
| EliquisApixaban | 113 | $80,092 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 114 | $69,522 |
| Nurtec OdtRimegepant Sulfate | 42 | $68,963 |
| OzempicSemaglutide | 70 | $68,682 |
| MounjaroTirzepatide | 50 | $60,316 |
| MyrbetriqMirabegron | 139 | $60,245 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess, Creon, Restasis | $913 | $624,9311,063 claims |
| Aimmune Therapeutics, Inc.Zenpep | $367 | $276,797285 claims |
| AstraZenecaFarxiga, Nexium, Symbicort, Breztri Aerosphere | $745 | $185,396426 claims |
| MerckJanumet, Januvia | $140 | $168,457281 claims |
| PfizerEliquis, Nurtec Odt, Lipitor | $175 | $159,568175 claims |
| Lilly USA, LLCMounjaro, Trulicity | $155 | $106,14099 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $480 | $106,004208 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat, Jentadueto, Stiolto Respimat | $111 | $69,530131 claims |
| Novo NordiskOzempic | $89 | $68,68270 claims |
| Astellas Pharma US IncMyrbetriq | $64 | $60,245139 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Dexilant | $187 | $44,158144 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $320 | $31,28952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Rego Park
- Matthew DavisRochester$76.6M
- Frank EderBinghamton$46.2M
- Suchet PatelEndwell$23.3M
- James WildGowanda$2.2M
- Michael FedericoEndwell$1.4M
- Donald BrautigamWestfield$1.3M
- Kimberly DesantisEndwell$1.1M
- Michael TugetmanHartsdale$1M
- Richard RuhOrchard Park$769K
- Eric LorraineEndwell$740K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.